Medexus

Medexus Pharmaceuticals press release (OTCQX:MEDXF): Q4 Adjusted EBITDA of $4.4 million in fiscal Q4 2024, a decrease of $0.4 million, or 8.8%, compared to $4.8 million in fiscal Q4 2023.  Adjusted net income of $0.8 million for fiscal Q4, 2024. Revenue of $26M (-9.1% Y/Y) misses by $0.68M. Available liquidity ofContinue Reading